ARTICLES BY WAYNE KOBERSTEIN

• Startups & Outsourcing — Opposite Poles or Virtual Partners?

  12/2/2015

  Let’s face it, finding the money often captures all but a few crumbs of the typical startup CEO’s attention. Laser-sharp illustrations in the company’s dog-and-pony show may present its scientific platform with convincing clarity and purpose, but traditionally, investment conferences have not been a place where the dollar-hungry startup talks about the infrastructure it must build or hire to turn its science into a medical product.

• Love Me, Love Me Not — The Life Science Industry's Paradox

  5/28/2015

  Cold-hearted logic dominates the quest for shareholder value, even as industry insiders complain that “nobody loves us.” What better example of the conundrum exists than the current commentary about Gilead and its wonder drugs for Hep C?

• Life Science Partnerships With Patient Foundations: Best Practices - Part 2

  7/1/2014

  Voices of BayBio’s “Successful Public-Private Partnerships” Survey

• Janet Woodcock's Quality Agenda At CDER

  2/2/2014

  New mandates, new user fees, and new uncertainties occupy the FDA’s drug center in 2014.

• Style & Substance In The Pharma Supplier Space

  11/27/2013

  What is real, and what is illusory in the world of drug, diagnostic, and device development?

• AstraZeneca Translates 'Winning With Science' From Words To Action

  8/29/2013

  An exclusive interview with Menelas Pangalos, executive VP of innovative medicines at AstraZeneca, one of the three direct-to-CEO reports, responsible for small-molecule discovery and early-stage (through Phase 2) development.

• Companies To Watch: StemCells

  4/1/2013

  StemCells has a cautious agenda in developing tissue-derived adult stem cell therapeutics that could lead to big leaps in patients’ quality of life.

• The New Pfizer Research Strategy: Openness And Collaboration Replace The Old Imperial Model

  6/28/2012

  Pfizer’s new research strategy headed by Jose-Carlos Gutierrez-Ramos, has a mission to “entrepreneurialize” discovery and development and bring together three main forces in drug research: academia, biotechnology, and pharmaceuticals.. By Wayne Koberstein, contributing editor

• Top 10 Pitfalls Of Life Sciences Partnering: Part 2

  6/1/2012

  The top 10 partnering pitfalls for life science companies that can ruin their chances for a successful partnership and expert advice for avoiding them. 

• Top 10 Pitfalls Of Life Sciences Partnering: Part 1

  4/30/2012

  The mandates to serialize all pharmaceutical products are as challenging for pharmaceutical manufacturers as the Y2K situation was to computer software engineers. 

• Personalized Medicine — Snapshot Of An Early Race

  9/12/2011

  One important caveat of the Diaceutics report is omission of key criteria: planning and intent. Have companies that launched themselves furthest into PM done so from an a priori belief in the concept or because they were reacting to untoward developments — such as efficacy and safety problems emerging for products already on the market? By Wayne Koberstein

• Leader In Transition

  6/9/2011

  Total dedication to job and family leaves little room for distractions. “The reason I don’t have any hobbies is that I spend all my free time with my family,” says Carrie Cox. By Wayne Koberstein, Life Science Leader magazine